SPL7013 |
|
|
Brand Name: VivaGel |
Drug Class: Microbicides
|
SPL7013, also known as VivaGel, is a type of medicine called a microbicide. Microbicides are substances that protect the body from infection by microorganisms such as bacteria, viruses, and fungi. Microbicides work by either destroying the microbes or preventing them from establishing an infection.
|
|
|
|
HIV/AIDS-Related Uses
|
|
|
|
SPL7013 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection. SPL7013 is also being studied for the prevention of other sexually transmitted infections including herpes simplex virus-2 (HSV-2), the virus that causes genital herpes.
|
|
|
|
This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people.
|
|
|
|
Dosage Form/Administration
|
|
|
|
SPL7013 comes in gel form and is applied vaginally with a single-use, prefilled vaginal applicator.
|
|
|
|
Recommended Daily Dose
|
|
|
|
SPL7013 has been given once or twice a day, every day, for up to 2 weeks in safety, tolerability, and acceptability studies. A 3% preparation of SPL7013 has been and is currently being evaluated in clinical trials.
|
|
|
|
Contraindications
|
|
|
|
Individuals should tell a doctor about any medical problems before taking this medicine.
|
|
|
|
Possible Side Effects
|
|
|
|
Along with its desired effects, SPL7013 can cause some unwanted effects. Although not all of these effects are known, stomach pain and painful urination have been reported.
|
|
|
|
Drug and Food Interactions
|
|
|
|
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.
|
Clinical Trials
|
Click here to search ClinicalTrials.gov for trials that use SPL7013.
|
Manufacturer Information
|
SPL7013 Starpharma Ltd PO Box 6535 St. Kilda Road Central Melbourne, Victoria, Australia 61385322736
|
Updated October 6, 2008
|